Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
HEALTHCARE TRIANGLE INC (HCTI)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$3.59-22.29%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HCTI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage dilution and debt from recent convertible notes and share issuance | A supporting condition in HEALTHCARE TRIANGLE INC's published investment case. The stated target is No further large dilutive issuances or debt beyond current agreements. | Under Pressure | New significant debt or share issuances that dilute equity or increase leverage materially | 9.7M shares issued (Jul 2026) vs no new dilution target 9.7M shares issued in July 2026; Equity Purchase Agreement amended in Sept 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making company with a volatile management record, not a proven durable compounder. Its long-term thesis is in a watch state: recent performance trails its industry cohort, and the risk label recently rose from elevated to high.
The evidence describes HCTI as cheap versus peers, but the valuation model has low confidence. The expectations gap is negative, while the overall priced-in tag is justified and no fragility gates fired, so the evidence does not point to clearly excessive market expectations.
Near term, erratic earnings and a 46% estimated miss probability make the next report an important risk point. Over the multi-year view, execution depends on integrating acquisitions, managing debt and equity transactions, and improving financial performance and cash flow; each priority remains under watch.
A guidance cut on the next call would add pressure, while continued weakening in jobs data could raise recession concerns for cyclical healthcare names. Continued earnings strength and higher guidance from sector peers could support sector momentum, but the evidence does not establish that HCTI itself is improving.
For the next 1 to 3 years, HCTI’s thesis hinges on better execution and financial performance amid high risk, with sector support as a possible counterweight. The evidence is medium-confidence and does not yet show a fresh break in the thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrows toward -$10 by FY27 | A primary condition in HEALTHCARE TRIANGLE INC's published investment case. The stated target is EPS loss improves to >= -10.14 USD_PER_SHARE. | Broken | EPS loss worsens or stays below -16 in FY26 or FY27 | Diluted EPS: $-1.56 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -10.14 USD_PER_SHARE. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-1.56 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful integration of acquisitions and platform agreements | A supporting condition in HEALTHCARE TRIANGLE INC's published investment case. The stated target is Sustained progress and integration milestones met in 2026-2027. | Intact | Failure to integrate acquisitions or platform deals causing stalled growth | Qualitative: 6 new contracts signed Company signed six client contracts in Spain, reinforcing growth through acquisitions and asset integration. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $38 million by FY27 | A primary condition in HEALTHCARE TRIANGLE INC's published investment case. The stated target is >=38 USD_MILLIONS. | Intact | revenue falls below $34 million in FY25 or fails to grow toward $38 million by FY27 | Revenue: $9.193M FY2026-Q2; GAAP. Published target: >=38 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20269,193,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-10.14 → $-63.60 · observed estimates
$0.05B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-25 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-26 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-27 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-28 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-29 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-30 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-07-31 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-08-01 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-02 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-03 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-04 | $-10.14 | $45,634,000 | 1 / 1 |
| 2026-08-05 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-06 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-07 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-08 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-09 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-10 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-12 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-13 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-14 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-15 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-16 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-17 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-18 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-19 | $-0.78 | $45,634,000 | 1 / 1 |
| 2026-08-20 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-21 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-22 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-23 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-24 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-25 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-26 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-27 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-28 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-29 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-30 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-08-31 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-01 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-02 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-03 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-04 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-05 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-06 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-07 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-08 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-09 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-10 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-11 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-12 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-13 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-14 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-15 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-16 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-17 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-18 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-19 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-20 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-21 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-22 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-23 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-24 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-25 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-26 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-27 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-28 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-29 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-09-30 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-01 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-02 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-03 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-04 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-05 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-06 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-07 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-08 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-09 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-10 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-11 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-12 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-13 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-14 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-15 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-16 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-17 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-18 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-19 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-20 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-21 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-22 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-23 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-24 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-25 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-26 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-27 | $-3.18 | $40,541,000 | 1 / 1 |
| 2026-10-28 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-10-29 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-10-30 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-10-31 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-11-01 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-11-02 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-11-03 | $-63.60 | $40,541,000 | 1 / 1 |
| 2026-11-04 | $-63.60 | $40,541,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.